What are the expected FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone) levels in patients on Hormone Replacement Therapy (HRT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

FSH and LH Levels in Patients on Hormone Replacement Therapy

FSH and LH levels are typically suppressed in patients on hormone replacement therapy (HRT) due to the negative feedback mechanism of exogenous hormones on the hypothalamic-pituitary axis. 1

Mechanism of Suppression

Hormone replacement therapy affects gonadotropin levels through:

  • Negative feedback mechanism: Exogenous estradiol suppresses the secretion of gonadotropin-releasing hormone (GnRH), which in turn reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland 1

  • Degree of suppression: The extent of suppression depends on the type, dose, and route of administration of HRT

Expected Hormone Levels by HRT Type

Estrogen-Based HRT

  • FSH suppression: Typically reduced by 39-52% from baseline values 2
  • LH suppression: Typically reduced by 32-64% from baseline values 2
  • Measurement timing: Levels should be assessed after at least 1-2 months of consistent therapy to reflect steady-state suppression 3

Testosterone Replacement Therapy

  • In primary hypogonadism: Before treatment, testosterone levels are low while FSH and LH are elevated above normal range 4
  • In hypogonadotropic hypogonadism: Before treatment, testosterone levels are low with normal or low gonadotropin levels 4
  • During treatment: Exogenous testosterone further suppresses already low or normal gonadotropin levels 4

Clinical Implications

Diagnostic Challenges

  • Masked ovarian function: HRT suppresses gonadotropins, making it impossible to accurately assess true ovarian function while on therapy 1
  • Monitoring recommendations: To accurately evaluate the hypothalamic-pituitary-gonadal axis, hormone measurements should be taken after temporarily discontinuing HRT 1

Special Populations

Premature Ovarian Insufficiency (POI)

  • Before treatment: FSH levels are typically elevated (within menopausal range) 5
  • During treatment: HRT normalizes hormone levels and alleviates symptoms 5, 6
  • Monitoring: Different HRT regimens may require different dosage adjustments to achieve symptom relief and hormone correction 6

Post-Chemotherapy Patients

  • Response patterns: Various HRT regimens in chemotherapy-induced POF show decreases in estradiol and progesterone with increases in FSH and LH toward physiological ranges 6

Age-Related Considerations

  • Older postmenopausal women: Despite lower baseline LH and FSH levels compared to younger postmenopausal women, they show similar responses to gonadal steroid feedback 7
  • GnRH secretion: Increases with age but decreases with estrogen and progesterone feedback 7

Common Pitfalls and Recommendations

  • Misinterpretation of levels: Normal menstrual cycles during HRT do not necessarily indicate normal fertility, as gonadotropin levels may be artificially suppressed 1

  • Inaccurate assessment: Do not use FSH/LH levels to assess ovarian function while on HRT; these measurements are unreliable during therapy 1

  • Timing of measurements: For accurate assessment of ovarian function, hormone levels should be measured after temporarily discontinuing HRT for at least 2-4 weeks 1

  • Treatment monitoring: When monitoring response to HRT, focus on symptom relief rather than absolute hormone values 2, 6

By understanding these expected patterns of gonadotropin suppression during HRT, clinicians can better interpret laboratory results and avoid diagnostic errors when evaluating patients on hormone replacement therapy.

References

Guideline

Hormonal Effects of Estradiol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Estrogen replacement therapy in postmenopausal women: a study of the efficacy of estriol and changes in plasma gonadotropin levels.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2001

Research

Transdermal estrogen replacement therapy in normal perimenopausal women: effects on pituitary-ovarian function.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1996

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.